Medilux Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
About Medilux Drugs
Medilux Drugs Private Limited (MDPL) is a Private Limited Indian Non-Government Company incorporated in India on 11 August 2020 (Four years and five months 22 days old ). Its registered office is in Indore, Madhya Pradesh, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Kewalramani and Verkha Kewalramani serve as directors at the Company.
Company Details
-
Location
Indore, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24290MP2020PTC052255
-
Company No.
052255
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
11 Aug 2020
-
Date of AGM
29 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Medilux Drugs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Kewalramani
|
Director | 11-Aug-2020 | Current |
|
Verkha Kewalramani
|
Director | 04-Jan-2023 | Current |
Financial Performance of Medilux Drugs.
Enhance accessibility to Medilux Drugs's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Medilux Drugs?
Unlock access to Medilux Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Medilux Laboratories Pvt LtdSanjay Kewalramani is a mutual person
-
Medilux Healthcare Private Limited
Sanjay Kewalramani is a mutual person
-
Medilux Chemicals Private Limited
Sanjay Kewalramani and Verkha Kewalramani are mutual person
-
Medilux Diagnostics Private Limited
Sanjay Kewalramani is a mutual person
-
Medilux Pharma LlpSanjay Kewalramani and Verkha Kewalramani are mutual person
-
Deepaksan Tradex Llp
Sanjay Kewalramani is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Medilux Drugs?
Medilux Drugs has a workforce of 0 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Medilux Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Medilux Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
